Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation;Implicaciones clínicas y farmacocinéticas del uso de dabigratan para la prevención de accidentes cerebrovasculares en fibrilación atrial no-valvular en pacientes con insuficiencia renal severa

Annals of Pharmacotherapy

Volumn 46, Issue 7-8, 2012, Pages 1105-1110

  Mack, Diana R ^a   Kim, Jenny J ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b SHENANDOAH UNIVERSITY   (United States)

Author keywords

Bleeding; Dabigatran etexilate; Pharmacokinetics; Renal impairment

Indexed keywords

AMIODARONE; DABIGATRAN; DRONEDARONE;

AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HEMOPERICARDIUM; HEMORRHAGIC SHOCK; HUMAN; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; STROKE; THROMBIN TIME; THROMBOEMBOLISM; UPPER GASTROINTESTINAL BLEEDING;

EID: 84864769237     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R057     Document Type: Article

References (16)

1. DeCaterina R, Hylek EM. Stroke prevention in atrial fibrillation: current status and near-future directions. Am J Med 2011;124:793-799.
2. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47:285-295.
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
4. Product information. Pradaxa (dabigatran etexilate mesylate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., January 2012.
5. Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 2012;52:119S-125S.
6. Drug safety communication-safety review of post-market reports of serious bleeding events. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm (accessed 2011 Dec 10).
7. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012;46:e10. doi: 10.1345/aph.1Q747.
8. Barton CA, McMillian WD, Raza S, et al. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy 2012;32:e103-e107. doi: 10.1002/j.1875-9114.2012.01036.x.
9. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171:1285-1288.
10. Cano EL, Miyares MA. Clinical challenge in a patient with dabigatraninduced fatal hemorrhage. Am J Geriatr Pharmacother 2012;10:160-163. doi: 10.1016/j.amjopharm.2012.02.004.
11. Boehringer Ingelheim Pharmaceuticals, Inc. Advisory committee briefing document. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf (accessed 2011 Nov 20).
12. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-268.
13. Lehr T, Haertter S, Liesenfeld K-H, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2011. Epub 28 Sept 2011. doi: 10.1177/0091270011417716
14. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363-1369.
15. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;20:705-711.
16. Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072127.pdf (accessed 2011 Nov 15).